Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does MEPOLIZUMAB Cause Prostatic specific antigen increased? 11 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 11 reports of Prostatic specific antigen increased have been filed in association with MEPOLIZUMAB (Nucala). This represents 0.0% of all adverse event reports for MEPOLIZUMAB.

11
Reports of Prostatic specific antigen increased with MEPOLIZUMAB
0.0%
of all MEPOLIZUMAB reports
0
Deaths
1
Hospitalizations

How Dangerous Is Prostatic specific antigen increased From MEPOLIZUMAB?

Of the 11 reports, 1 (9.1%) required hospitalization.

Is Prostatic specific antigen increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for MEPOLIZUMAB. However, 11 reports have been filed with the FAERS database.

What Other Side Effects Does MEPOLIZUMAB Cause?

Asthma (11,033) Dyspnoea (9,192) Wheezing (6,093) Product dose omission issue (5,873) Cough (4,577) Pneumonia (4,107) Therapeutic product effect incomplete (4,106) Drug ineffective (3,880) Loss of personal independence in daily activities (3,566) Fatigue (2,656)

What Other Drugs Cause Prostatic specific antigen increased?

ENZALUTAMIDE (3,731) LEUPROLIDE (2,432) ABIRATERONE (1,581) RADIUM RA-223 DICHLORIDE (449) RELUGOLIX (335) BICALUTAMIDE (322) DOCETAXEL (282) APALUTAMIDE (251) DENOSUMAB (220) LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (212)

Which MEPOLIZUMAB Alternatives Have Lower Prostatic specific antigen increased Risk?

MEPOLIZUMAB vs MEPROBAMATE MEPOLIZUMAB vs MERCAPTOPURINE MEPOLIZUMAB vs MEROPENEM MEPOLIZUMAB vs MEROPENEM ANHYDROUS MEPOLIZUMAB vs MESALAMINE

Related Pages

MEPOLIZUMAB Full Profile All Prostatic specific antigen increased Reports All Drugs Causing Prostatic specific antigen increased MEPOLIZUMAB Demographics